Understanding the DMPS Shortage: What It Means for Chelation Therapy

If you’ve been researching chelation therapy, you may have noticed that one medication—DMPS—has become increasingly difficult to obtain. Patients across the country are asking the same questions:

  • Why is DMPS unavailable?
  • Has DMPS been discontinued?
  • What happens if my provider previously recommended DMPS?
  • Are there other options available?

The short answer is that the DMPS shortage has made it difficult to source the medication through many compounding pharmacies due to ongoing pharmaceutical supply chain challenges and regulatory factors affecting compounded medications. [1-3]

While this change has understandably created uncertainty, it doesn’t necessarily mean that chelation therapy is no longer an option. Modern medicine is constantly evolving, and one of the strengths of personalized care is the ability to thoughtfully adapt when circumstances change.

At ViveWell Health, we believe informed patients make confident decisions. Understanding why medication shortages happen—and what they mean for your care—is an important part of that process.

What Is DMPS?

DMPS, short for 2,3-Dimercapto-1-propanesulfonic acid, is a chelating agent that has been used by some healthcare providers as part of individualized treatment plans when chelation therapy is considered appropriate. [1]

Chelation therapy refers to the use of specialized compounds that bind to certain metals within the body so they can be eliminated through normal physiological processes. Different chelating agents have different characteristics, which is why treatment recommendations should always be individualized rather than based on a one-size-fits-all approach. [1,4]

Unlike many prescription medications available through traditional pharmacies, DMPS has historically been obtained in the United States through licensed compounding pharmacies. [2] Because compounded medications rely on pharmaceutical-grade raw ingredients and specialized preparation, they are more susceptible to changes in manufacturing, supplier availability, and regulatory oversight than commercially manufactured medications.

For many years, DMPS has been one of several tools available to healthcare providers who offer personalized chelation protocols. However, like any compounded medication, its availability depends on a complex network of manufacturers, ingredient suppliers, pharmacies, and regulatory standards.

Why Is DMPS Currently Unavailable?

According to reports from compounding pharmacies and current regulatory guidance, DMPS availability has been affected by challenges involving pharmaceutical ingredient sourcing and the regulatory requirements governing compounded medications. Like many compounded medications, DMPS depends on the availability of pharmaceutical-grade raw ingredients and specialized manufacturing processes. When either of those is disrupted, temporary supply limitations can occur. [1-3]

1. Raw Ingredient Availability

Compounding pharmacies can only prepare medications when pharmaceutical-grade active ingredients are available from qualified suppliers. If those ingredients become difficult to obtain, pharmacies may be unable to produce the medication until supply resumes. [3]

In the case of DMPS, many pharmacies have reported difficulty sourcing the pharmaceutical-grade compound needed to prepare both injectable and oral formulations.

2. Regulatory Oversight

Compounded medications are subject to rigorous federal and state regulations designed to promote patient safety and medication quality. The U.S. Food and Drug Administration (FDA) continues to strengthen oversight of pharmaceutical manufacturing and compounding practices, which can occasionally affect the availability of certain medications. [3]

These regulations are intended to help ensure that compounded medications meet appropriate quality standards, but they can also contribute to temporary interruptions in availability when manufacturers or suppliers experience compliance challenges.

3. Pharmaceutical Supply Chain Challenges

Medication shortages have become increasingly common throughout healthcare over the past several years. Manufacturing delays, transportation disruptions, limited raw materials, and increased demand have affected everything from antibiotics and injectable medications to specialized compounded therapies. [5]

DMPS is one example of how these broader supply chain issues can impact access to certain medications.

Illustration showing the primary causes of the DMPS shortage, including pharmaceutical raw material availability, FDA regulatory oversight, and global pharmaceutical supply chain disruptions affecting compounded medications.

While shortages can be frustrating for both patients and healthcare providers, they are not unique to chelation therapy. Similar challenges continue to affect many areas of modern medicine.

Does This Mean Chelation Therapy Is No Longer Available?

Not necessarily.

One of the most common misconceptions is that chelation therapy depends on a single medication. In reality, chelation therapy is an approach to care—not one specific drug. [4]

Healthcare providers have multiple chelating agents available, each with its own characteristics, clinical considerations, and potential applications. Which option, if any, may be appropriate depends on many factors, including:

  • Your health history
  • Current symptoms
  • Laboratory findings
  • Previous treatments
  • Overall health goals
  • Medication availability

Rather than following the same protocol for every patient, personalized medicine allows providers to evaluate these factors together and determine the most appropriate course of care.

This individualized approach becomes especially valuable when medication availability changes. Instead of ending treatment because one medication is temporarily unavailable, providers can reassess the overall plan and discuss whether another evidence-informed option may be appropriate.

Are There Alternatives to DMPS?

While the current DMPS shortage has created challenges for patients and providers alike, it does not mean that chelation therapy is no longer an option.

It’s important to understand that different chelating agents are designed to bind to different metals. DMPS has long been recognized for its strong affinity for mercury, while EDTA has been widely used to support the removal of certain other heavy metals, including lead. Because these medications have different properties, they are not direct substitutes for one another. [4,6]

For many patients, however, the current shortage of DMPS does not mean treatment must come to a halt. EDTA remains an available option for chelation of certain heavy metals, while treatment plans specifically targeting mercury may require a different approach until DMPS becomes available again. [4,6]

Chelation therapy has always been a personalized treatment. The most appropriate chelating agent depends on an individual’s health history, laboratory findings, treatment goals, and the specific metals being addressed. Your healthcare provider will determine the treatment strategy that best aligns with your unique clinical needs. [4]

Laboratory illustration of EDTA (ethylenediaminetetraacetic acid) and DMSA (dimercaptosuccinic acid) chelating agent bottles with chemical structures, representing alternative compounds used in individualized heavy metal chelation protocols.

EDTA

Ethylenediaminetetraacetic acid (EDTA) is one of the most widely recognized chelating agents and has been used in a variety of clinical settings for decades. It has established medical applications and may also be incorporated into individualized chelation protocols when appropriate. [4]

DMSA

Dimercaptosuccinic acid (DMSA) is another chelating agent that may be appropriate in certain situations. Depending on the patient’s health history and provider recommendations, DMSA may be used as part of an individualized protocol. [4,6]

Have Questions?

If you’re currently receiving chelation therapy or were planning to begin treatment, we encourage you to contact us ViveWell Health.

Our providers can review your treatment plan, discuss available alternatives, and help determine the next step that’s right for you.

Personalized care doesn’t stop when a medication becomes unavailable. It adapts—so your health journey can continue with confidence.

Already Scheduled?

If you already have a DMPS infusion scheduled or were expecting an oral prescription refill, our team will contact you regarding next steps.

In many situations, we may recommend scheduling a follow-up consultation so your provider can:

  • Review your current treatment plan
  • Discuss available medication options
  • Determine whether an alternative protocol is appropriate
  • Answer any questions you may have before continuing care

Our goal is to make any transition as smooth and personalized as possible.

Healthcare Is Always Evolving. So Is ViveWell.

Medicine is constantly advancing. New research emerges, regulations evolve, manufacturing challenges arise, and occasionally a medication or therapy becomes temporarily unavailable. While these changes are often outside the control of healthcare providers, how a practice responds makes all the difference.

At ViveWell Health, we are committed to providing thoughtful, uninterrupted care whenever possible. When a medication becomes difficult to source, a protocol changes, or new evidence guides a different approach, our focus remains the same: helping patients continue moving forward with confidence.

Rather than relying on a single product or protocol, we practice personalized medicine. That means evaluating the whole person, staying informed on the latest evidence, and adapting treatment plans when appropriate to meet each patient’s unique needs.

The current DMPS shortage is one example of that commitment in action. When circumstances change, our providers carefully review available options, discuss them with each patient, and adjust care plans as needed to help maintain continuity of care whenever clinically appropriate.

Our goal isn’t simply to offer a specific therapy. It’s to provide comprehensive, individualized care that can adapt alongside advances in medicine, changing regulations, and real-world challenges such as medication shortages.

While the tools available to us may change over time, our commitment to delivering personalized, evidence-informed care never does.

If you have questions about the current availability of DMPS, are exploring chelation therapy, or would like to learn more about personalized treatment options, we’re here to help. Our team is happy to discuss your health goals, answer your questions, and help determine the approach that best fits your individual needs.

Ready to learn more? Schedule a FREE Discovery Call with ViveWell Health and discover how personalized, whole-person care can help you move forward with confidence.

References

1. National Center for Biotechnology Information (NCBI). Chelation Therapy. StatPearls Publishing.
https://www.ncbi.nlm.nih.gov/books/NBK562888/

2. Aposhian HV. DMPS—Mercury Chelation and Clinical Use. Journal of Toxicology: Clinical Toxicology.
https://pmc.ncbi.nlm.nih.gov/articles/PMC2366051/

3. U.S. Food and Drug Administration (FDA). Human Drug Compounding.
https://www.fda.gov/drugs/human-drug-compounding

4. Flora SJS, Pachauri V. Chelation in Metal Intoxication. International Journal of Environmental Research and Public Health. 2010;7(7):2745-2788.
https://pmc.ncbi.nlm.nih.gov/articles/PMC2922724/

5. American Society of Health-System Pharmacists (ASHP). Drug Shortages Resource Center.
https://www.ashp.org/drug-shortages

6. Sears ME. Chelation: Harnessing and Enhancing Heavy Metal Detoxification—A Review. International Journal of Environmental Research and Public Health. 2013;10(12):6345-6369.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3654245/